Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest Content
Archive
For authors
About
Podcasts
Search for this keyword
Advanced search
Close
More
Main menu
Latest Content
Archive
For authors
About
Podcasts
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
biologic disease-modifying antirheumatic drugs
Email alerts
biologic disease-modifying antirheumatic drugs
Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses
Ernest
Choy
,
Nick
Freemantle
,
Clare
Proudfoot
,
Chieh-I
Chen
,
Laurence
Pollissard
,
Andreas
Kuznik
,
Hubert
Van Hoogstraten
,
Erin
Mangan
,
Paulo
Carita
,
Thi-Minh-Thao
Huynh
RMD Open
Feb 2019,
5
(1)
e000798;
DOI:
10.1136/rmdopen-2018-000798
Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip J
Mease
,
Chitra
Karki
,
Mei
Liu
,
Arthur
Kavanaugh
,
Christopher T
Ritchlin
,
Doquyen Hoa
Huynh
,
Jacqueline B
Palmer
,
Jeffrey D
Greenberg
RMD Open
Apr 2018,
4
(1)
e000638;
DOI:
10.1136/rmdopen-2017-000638
Special collections
Guidelines, Recommendations and Consensus Statements
Press releases
(1)